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Abstract
Purpose Vitamin D, parathyroid hormone (PTH) and cal-
cium in blood are correlated with each other. Previous
studies have suggested vitamin D to have anti-proliferative
effects on tumor cells, whereas PTH may have carcinogenic
effects. A cancer disease may influence calcium levels in
blood, but less is known about calcium and its potential effect
on cancer risk and survival. The aim of this study was to
examine pre-diagnostic levels of vitamin D (25OHD), PTH
and calcium in relation to survival after breast cancer.
Methods The Malmo¨ Diet and Cancer Study enrolled
17,035 women between 1991 and 1996. 672 patients devel-
oped incident invasive breast cancer up until 31 December
2006. Serum samples collected at baseline were analyzed for
25OHD, PTH and calcium. All patients were followed until 31
December 2010 using the Swedish Cause of Death Registry.
The analytes were divided into tertiles and the risk of death
from breast cancer was analyzed using an adjusted Cox pro-
portional hazards analysis, yielding hazard ratios with 95 %
confidence intervals.
Results Levels of 25OHD and breast cancer mortality
were associated in a u-shaped manner with the highest
mortality among patients in the first (2.46: 1.38–4.37) and
third tertiles (1.99: 1.14–3.49), as compared to the second.
An inverse relation was found between calcium levels and
breast cancer mortality, with the lowest mortality in the
third tertile, (0.53: 0.30–0.92) as compared to the first.
There was no clear association between PTH and breast
cancer mortality.
Conclusions This study shows that pre-diagnostic 25OHD
and calcium may affect survival following breast cancer.
Keywords Breast cancer  Calcium  Mortality  PTH 
Survival  Vitamin D
Introduction
Vitamin D has been suggested to have anti-proliferative
effects on breast tumor cells in animal and in vitro studies [1].
Ecological studies have shown a difference in breast cancer
incidence and survival related to geography, suggesting a
beneficial effect of vitamin D levels due to solar exposure [2–
4] and others have shown a better survival in patients diag-
nosed with breast cancer during summer and autumn [5, 6].
Several prospective epidemiological studies have
investigated the relationship between vitamin D and breast
cancer incidence, but with conflicting results [1, 7–9]. A
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recent meta-analysis of studies which had measured vita-
min D levels (25OHD in serum or plasma) close to diag-
nosis in early stage breast cancer, found an association
between low levels of vitamin D and a high mortality, i.e.,
a poor survival [10]. Only one study has previously
investigated pre-diagnostic serum levels of vitamin D in
relation to breast cancer mortality among breast cancer
patients. Freedman et al. [11] found an inverse relationship
between low pre-diagnostic levels of vitamin D (25OHD)
and high breast cancer mortality.
Levels of vitamin D and parathyroid hormone (PTH) are
inversely correlated with each other [12], and both influ-
ence the level of calcium in blood. PTH is secreted from
the parathyroid gland when calcium levels are low and
stimulates release of calcium from bone into blood and
synthesis of active vitamin D (1,25(OH)2D) from its stor-
age form (25OHD). It has been suggested in experimental
studies that PTH has a carcinogenic and tumor promoting
effect [13–16], and it has also been indicated that primary
hyperparathyroidism may increase the risk of breast cancer
[17–20]. To our knowledge, no previous study has inves-
tigated the relationship between levels of PTH and breast
cancer survival.
It is well known that calcium levels may be increased
following different cancer forms. One previous study has
shown an increased incidence of breast cancer with high
pre-diagnostic calcium levels [21]. It is, however, unknown
what impact pre-diagnostic calcium levels may have on
breast cancer survival. Since calcium has been shown to be
an important intracellular messenger, involved in prolifer-
ation, apoptosis and cell signaling [22], it is possible to
hypothesize that calcium may affect survival following
breast cancer.
In 1991, inclusion in a population-based prospective
cohort study began in Malmo¨, creating The Malmo¨ Diet
and Cancer Study (MDCS), including 17,035 women.
Blood samples taken at baseline are now available for
analysis.
Our main hypothesis is that low vitamin D (25OHD) is
associated with a poor survival following breast cancer, i.e.,
a high mortality among cases. Our secondary hypothesis is
that high pre-diagnostic PTH is also associated with a poor
survival. As a third explorative analysis, we investigated if
calcium also had an effect on survival.
Materials and methods
The Malmo¨ Diet and Cancer Study (MDCS)
Between 1991 and 1996, all residents in the Southern
Swedish city of Malmo¨, born 1923–1950, were invited to
participate in a population-based prospective cohort study.
A total of 41 % of eligible subjects participated and 17,035
women completed the baseline examination [23]. Written
informed consent was obtained from all participants.
Baseline examination included a dietary assessment and a
self-administered questionnaire on different life-style fac-
tors. Moreover, a trained nurse performed anthropometric
measurements and blood samples were drawn. Subjects
were included, and had their blood samples drawn, evenly
over the calendar year, except for less recruitment in
December and June, and none in July. The ethical com-
mittee in Lund, Sweden, approved the MDCS (LU 51-90),
and the present study (Dnr 652/2005 and Dnr 23/2007).
Study population
For identification of breast cancer cases within the MDCS
cohort, The Swedish Cancer Registry was used. Prior to
baseline examination, 576 out of the 17,035 women were
diagnosed with breast cancer. These women were catego-
rized as prevalent breast cancer cases and therefore
excluded from the current analysis. In all, 766 women were
diagnosed with breast cancer up until December 31, 2006,
but two incident cases had not donated blood at baseline
[7]. We found that 77 tumors were cases of ductal cancer
in situ, and these cases were excluded as the present study
intended to examine survival, i.e., there is a very low
mortality, if any, associated with in situ breast cancer.
Another 15 cases were excluded due to bilateral cancer, as
it was difficult to interpret information about tumor char-
acteristics in these cases. Finally, a total of 672 women
with invasive unilateral breast cancer were included in the
present analysis. Mean time from baseline examinations to
diagnosis was 7.12 years with a standard deviation (SD) of
3.82.
Clinical information
Information on type of surgery and planned adjuvant therapy,
recommended by a treatment conference immediately fol-
lowing surgery, was retrieved from clinical notes. Some 41 %
(n = 272) underwent mastectomy, and 57 % (n = 382) had a
partial mastectomy. Lymph nodes were examined after sen-
tinel node biopsy in 26 % (n = 173) and after axillary dis-
section in 62 % (n = 416). Adjuvant treatment with
radiotherapy was planned for 54 % (n = 361) of patients,
endocrine treatment in 46 % (n = 312), and 14 % (n = 92)
were planned for chemotherapy, Table 1.
Histopathological analysis
Information on laterality, tumor size and lymph node
metastasis was retrieved from medical records and histo-
pathological reports. All invasive tumors, diagnosed
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between 1991 and 2004, were pathologically re-evaluated
by one senior pathologist. The re-evaluation concerned
tumor invasiveness, tumor type according to WHO and
grading according to Elston–Ellis [24, 25]. Tumors diag-
nosed between 2005 and 2006 were classified according to
WHO type and Elston–Ellis grade at diagnosis, thus
information was readily available from clinical notes and
pathology reports. Estrogen receptor status (ER) and pro-
gesterone receptor status (PgR) on all tumors were evalu-
ated with tissue microarray technique (TMA), using
immunohistochemical (IHC) analysis with specific anti-
bodies as described in detail previously [25]. In line with
Swedish clinical practice, the cutoff points for dichoto-
mizing tumors, as being negative or positive, were 0–10
and 11–100 % positive nuclei, respectively.
Laboratory analysis
At baseline examination, serum was extracted within 1 h
from venipuncture and samples were thereafter stored at
-80 C [26]. Serum from identified cases of breast cancer
was retrieved from the MDCS bio bank and analyzed for
25OHD, PTH and calcium. The samples had not been
previously thawed. High-pressure liquid chromatography
(HPLC) was used to analyze 25OHD3, and laboratory
analysis was successful in 655 out of 672 cases in the
present study population. PTH was analyzed with the Im-
munolite 2000 Intact PTH immunoassay (Diagnostic
Products corporation, Los Angeles, CA), 664 successful
analyses. Total calcium was successfully analyzed in 661
cases by neutral carrier ion-selective electrode [27].
Unsuccessful analyses were due to inadequate volume or
quality of sera. The analysis of blood samples was per-
formed during 2007 as part of a previous case–control
study and has previously been described in detail [7].
Endpoint retrieval
The Swedish Cause of Death Registry was used to identify
cases that had deceased as well as their cause and date of
death. End of follow-up was the date of death, date of
emigration or December 31, 2010. Mean time from diag-
nosis until end of follow-up was 8.7 years (SD: 4.0).
Subsequently, the women were divided into three different
groups: (1) women still alive at end of follow-up; (2)
women with breast cancer as cause of death or with breast
cancer as a contributing cause of death which were clas-
sified as ‘‘dead from breast cancer,’’ i.e., ‘‘breast cancer-
specific mortality’’; and (3) women deceased from causes
unrelated to breast cancer (‘‘dead from other cause’’).














Mean (SD) in italics
Age at
baseline
56.3 (6.8) 58.3 (8.0) 61.8 (6.8) 57.0 (7.2)
Age at
diagnosis
63.7 (7.6) 64.6 (8.9) 67.8 (7.4) 64.2 (7.9)
Size
1–10 mm 159 (30.8) 3 (3.0) 17 (31.5) 179 (26.6)
11–20 mm 240 (46.6) 38 (37.6) 18 (33.3) 297 (44.2)
C21 mm 110 (21.5) 52 (51.5) 18 (33.3) 181 (26.9)
Unknown 6 (1.2) 8 (7.9) 1 (1.9) 15 (2.2)
Lymph node
status
Positive 128 (25.1) 63 (62.4) 11 (20.4) 204 (30.4)
Negative 384 (74.3) 36 (35.6) 42 (77.8) 462 (68.8)
Unknown 3 (0.6) 2 (2.0) 1 (1.9) 6 (0.9)
Distant
metastasis
Yes 0 (0.0) 9 (8.9) 0 (0.0) 9 (1.3)
No 514 (99.8) 91 (90.1) 54 (100.0) 661 (98.4)
Unknown 1 (0.2) 1 (1.0) 0 (0.0) 2 (0.3)
Nottingham
grade
I 150 (29.1) 8 (7.9) 16 (29.6) 175 (26.0)
II 244 (47.4) 31 (30.7) 20 (37.0) 296 (44.0)
III 90 (17.5) 48 (47.5) 14 (25.9) 152 (22.6)
Unknown 31 (6.0) 14 (13.9) 4 (7.4) 49 (7.3)
Histological
type
Ductal 345 (66.9) 66 (65.3) 33 (61.1) 445 (66.2)
Lobular 96 (18.8) 21 (20.8) 9 (16.7) 127 (18.9)
Other/
mixed
47 (9.1) 2 (2.0) 9 (16.7) 58 (8.6)




47 (9.1) 18 (17.8) 6 (11.1) 71 (10.6)
[10 % pos 380 (73.9) 63 (62.4) 43 (79.6) 488 (72.6)




183 (35.4) 50 (49.5) 28 (51.9) 261 (38.8)
[10 % pos 195 (37.9) 24 (23.8) 16 (29.6) 236 (35.1)
Unknown 137 (26.7) 27 (26.7) 10 (18.5) 175 (26.0)
Age at diagnosis and prognostic factors for breast cancer
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Statistical methods
Levels of 25OHD, PTH and calcium were divided into ter-
tiles. Survival was assessed as mortality from breast cancer
per 100,000 person-years. In order to test differences in
mortality between tertiles, a Cox’s proportional hazards
analysis, yielding hazard ratios (HR) and 95 % confidence
intervals (CI), was used. The assumption of proportional
hazards was met as tested by log—minus log plots.
The model was subsequently adjusted for factors known
to influence levels of 25OHD, PTH and calcium, such as
season of blood draw and age at baseline. In order to adjust
for storage time, year of baseline examination was included
in the model.
The Cox analysis was further adjusted for factors known
to affect survival following breast cancer such as age at
diagnosis, tumor size, lymph node status, the presence of
distant metastases, Nottingham grade, histological type, ER
status and PgR status. All confounders were tested one at a
time in the model in order to see which factor affected
hazard ratio (HR) the most.
As a sensitivity analysis, we adjusted our exposures for
each other. As an example, 25OHD was adjusted for the
other exposures, PTH and calcium, individually and
combined.
To assess the risk of reverse causality, we performed
sensitivity analyses, repeating all analyses, excluding
women diagnosed with breast cancer within 2 years from the
baseline examination (n = 82). Another sensitivity analysis,
in which the Cox analyses were also adjusted for different
types of adjuvant therapy, was also performed.
Moreover, we made sensitivity analyses in which we
stratified the analyses for premenopausal, respectively,
postmenopausal women at the time of diagnosis, and for
body mass index (BMI) \25 (considered normal weight)
versus BMI C25 (overweight).
Table 2 Vital status in relation
to treatment
Factor Vital status
Alive (n = 517) Dead breast
cancer (n = 101)
Dead other





Mastectomy 36.6 60.4 40.7 40.5
Partial mastectomy 61.7 31.7 57.4 56.8
Local excision or surgical biopsy 0.4 0.0 0.0 0.3
Unknown 1.4 7.9 1.9 2.4
Axillary surgery
No axillary dissection 9.9 5.9 20.4 10.1
Axillary dissection 58.6 75.2 68.5 61.9
Sentinel node biopsy 29.8 13.9 9.3 25.7
Singular node biopsy 0.4 0.0 0.0 0.3
Unknown 1.4 5.0 1.9 1.9
Planned adjuvant radiotherapy
No 36.0 35.6 53.7 37.4
Yes 53.4 61.4 42.6 53.7
Unknown 10.6 3.0 3.7 8.9
Planned adjuvant endocrine therapy
No 51.5 43.6 63.0 51.2
Yes 48.5 56.5 37.1 48.8
Anti-estrogen 37.9 43.6 29.6 38.1
Aromatase inhibitor 3.5 7.9 1.9 4.0
Other/unknown drug 4.6 2.0 5.6 4.3
Unknown 2.5 3.0 0.0 2.4
Planned adjuvant chemotherapy
No 78.3 63.4 90.7 77.1
Yes 10.6 33.7 5.6 13.7
Unknown 11.0 3.0 3.7 9.2
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Results
Out of 672 women, 101 had died due to breast cancer,
which gives a breast cancer-specific mortality of 1,738/
100,000 person-years. A comparison between different
outcomes and factors possibly affecting survival is pre-
sented in Table 1. Table 2 shows the distribution of treat-
ment in different groups defined the outcome.
There was a statistically significantly higher breast cancer-
specific mortality (HR) among patients in the first 1.84
(1.08–3.13) as well as the third 1.81 (1.06–3.07) tertile of
25OHD as compared to the second tertile (Table 3). In the
adjusted analysis, these associations were strengthened, fac-
tors that affected the results most were lymph node status and
distant metastasis, and remained statistically significant.
When studying pre-diagnostic levels of PTH, there was
also a higher breast cancer-specific mortality among sub-
jects in the first 1.31 (0.81–2.12) as well as in the third 1.20
(0.73–1.96) tertile (Table 3); however, the results were not
statistically significant. Several factors coincided to make
the associations disappear in the adjusted analysis, but
when adjusting for size of tumor and lymph node status, the
reduction was strongest (data not shown).
An inverse relationship was seen between calcium levels
and breast cancer-specific mortality, with lower mortality
among subjects within the third tertile 0.88 (0.54–1.44).
This association was not statistically significant in the
crude analysis, but it was stronger and turned statistically
significant 0.53 (0.30–0.92) when the analysis was adjusted
for known prognostic factors (Table 3). Factors adding
most to the stronger association were lymph node status
and distant metastasis.
In the adjusted analyses, where our studied exposures
were adjusted for the other exposures, all results remained
the same (data not shown).
In order to exclude women with subclinical breast cancer at
the time of baseline blood donation, we repeated analyses
excluding women diagnosed with breast cancer within 2 years
as a sensitivity analysis. We found similar associations
regarding 25OHD in the first tertile (2.22: 1.20–4.11), but sta-
tistical significance was lost for the third tertile (1.65:
0.89–3.06). No association could be seen between PTH levels
and breast cancer mortality in this analysis. There was still a low
mortality from breast cancer among patients with calcium levels
within the third tertile in the adjusted analysis, but this associ-
ation did not reach statistical significance (0.69: 0.37–1.30).
The sensitivity analysis adjusting also for adjuvant
therapy showed similar associations in all analyses (data
not shown).
Due to statistical instability in the premenopausal group
(n = 65), the stratified analyses on menopausal status
showed inconclusive results. In the postmenopausal group
Table 3 Tertiles of 25OHD3, PTH and Ca in relation to breast cancer mortality


















2 76–99 216 1,863 21 1,127 1 1 1






p trend: 0.95 p trend: 0.62 p trend: 0.51
PTH
(pmol/L)






2 2.96–4.41 220 2,000 30 1,500 1 1 1






p trend: 0.71 p trend: 0.70 p trend: 0.62
Calcium
(mmol/L)
1 B2.36 235 2,067 38 1,838 1 1 1












p trend: 0.61 p trend: 0.40 p trend: 0.02
a Crude analysis
b Adjusted for season and year of blood sample, and age at baseline
c Adjusted for same factors as b but also for age at diagnosis, size of tumor, Elston–Ellis grade, histological type, ER status, PGR status, lymph
node status and distant metastasis at diagnosis
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(n = 587), results were similar in all analyses, though con-
fidence intervals were somewhat widened (data not shown).
In the analyses, where we stratified for BMI, we noticed
that results were attenuated in the group with BMI C25
(n = 326), compared to the group with BMI \25
(n = 346), though this observation is inconclusive due to
low statistical power in the analysis (data not shown).
Discussion
We found a statistically significant u-shaped relationship,
between pre-diagnostic levels of 25OHD and breast cancer-
specific mortality, with higher mortality, i.e., poor survival,
among patients with 25OHD levels within the first and
third tertiles as compared to the second. There was no
association between PTH and breast cancer-specific mor-
tality. Regarding levels of calcium and breast cancer-spe-
cific mortality, we saw that patients within the highest
tertile had a lower mortality, i.e., a better survival.
Vitamin D and breast cancer
The finding that low 25OHD levels were associated with a high
breast cancer-specific mortality is in line with our hypothesis. It
is now well known that vitamin D inhibits growth of tumor-
derived cells from breast [28] and promote apoptosis in breast
cancer cells [29]. On a molecular level, active vitamin D
(1,25(OH)2D) has been shown to act as a cancer inhibitor in
many other ways, such as enhanced DNA repair, immuno-
modulation and protection against antioxidants, although there
are areas not yet understood [30, 31]. These mechanisms may
indeed explain the results seen in the present study.
One previous study has shown a better survival for breast-,
colon- and prostate cancer patients diagnosed during summer
or early fall, which would indicate advantages of adequate
vitamin D levels during treatment [6]. It has also been sug-
gested that less favorable outcome for African–American
women with breast cancer in the USA is due to lower habitual
vitamin D status among these women [32]. Directly measured
sufficient levels at diagnosis in early breast cancer have in other
studies been shown to improve survival [10, 33–37]. Experi-
mental and epidemiological studies taken together; they are
consistent with our finding that lower pre-diagnostic levels of
25OHD are related to poor survival. One study measuring
vitamin D before diagnosis found an inverse relationship
between pre-diagnostic levels of vitamin D (25OHD) and
breast cancer mortality [11]. When analyzing breast cancer
mortality, they choose to stratify 25OHD in two categories with
levels [62.5 and B62.5 nmol/L [11], hence they differ only
between high and low 25OHD. This cut point is within our first
tertile and is therefore also in line with our results.
To this date, there are no available guidelines regarding
adequate 25OHD levels, though the Committee of the Insti-
tute of Medicine has recommended 40–50 nmol/liter as a
lower acceptable level and that levels above 125 nmol/L
should raise concern among clinicians in North America [38].
These recommended clinical cut points are within the first,
respectively, third of our tertiles, and 5.9 % (n = 39) of our
subjects had levels underneath 50 nmol/L, 9.3 % (n = 62)
above 125 nmol/L.
In addition to the findings that women with low levels of
25OHD had a high mortality, i.e., a poorer survival, we found
that patients within the third tertile were also at a higher risk for
a breast cancer-related death. To date, this has not been shown
previously and the findings do not support our primary
hypothesis. However, a similar pattern, with a u-shaped rela-
tionship, between levels of 25OHD and risk of subsequent
prostate cancer has been found in our cohort [39]. Also, one
previous study on 25OHD levels measured at diagnosis and
overall mortality in postmenopausal breast cancer patients,
showed the lowest mortality among patients within the second
tertile [37]. Since most of the anti-carcinogenic effects of
vitamin D seem to be mediated by the vitamin D receptor
(VDR) [30], individual- or tumor-specific differences in VDR
may be of importance.
PTH and breast cancer
We did not find any association between levels of PTH and
breast cancer-specific mortality. Previous experimental
studies have suggested that PTH may be associated with poor
breast cancer survival due to carcinogenic and tumor pro-
moting effects [13–16], such as regulating angiogenesis and
osteoclastogenesis in bone metastasis by breast cancer cells
[40]. Therefore, our hypothesis was that there would be an
association. Due to intra-individual variation of PTH levels
[41, 42], there is a risk of misclassification, which might have
affected our results. There are no previous results reported
from epidemiological studies on PTH and breast cancer sur-
vival, and our explorative analysis is the first within the area.
Calcium and breast cancer
High levels of calcium at diagnosis of breast cancer have
previously been associated with large tumors, and this may
well be an effect of the tumor per se [43]. Previous findings
suggest an increased incidence and more aggressive breast
cancer tumor characteristics, associated with higher pre-
diagnostic calcium levels [7, 21, 44]. In contrast, our
explorative analysis found an association between high pre-
diagnostic levels of calcium and a lower breast cancer-specific
mortality. This finding needs further scientific attention, and
1136 Cancer Causes Control (2014) 25:1131–1140
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the expression or activity of the calcium receptor may mod-
ulate the effect of calcium on breast tumors.
Methodological issues
This study was performed using blood samples taken
before diagnosis. Therefore, the tumor itself cannot have
influenced the analyzed levels. The sensitivity analysis
excluding women diagnosed within 2 years from baseline
showed similar results regarding 25OHD and mortality
from breast cancer, but statistical significance was lost in
the upper tertile, assumingly due to loss of statistical power
with a decreasing number of outcomes, more precisely 94
deaths from breast cancer instead of 113.
It must be considered that there is only one blood
sample available for analysis, sometimes taken many years
before diagnosis, and it is possible that this sample does not
reflect the individuals’ habitual vitamin D, PTH and cal-
cium status. Previous studies have shown, though, that
25OHD measured at two times, several years apart have a
high correlation [45, 46].
Regarding PTH, it has been shown that there is a short-term
(up to 6 weeks) intra-individual variation of about 25 % [41,
42]. PTH also shows a relatively large circadian fluctuation
[41], and the time of the day for blood donation in the present
study has not been recorded [7]. Therefore, there is a risk of
misclassification of PTH levels that may have attenuated a
potential possibly obscure true association between pre-diag-
nostic levels of PTH and mortality from breast cancer. Contrary
to PTH, total serum calcium has been shown to have a low intra-
individual variation over short as well as long time [47, 48].
Vitamin D levels tend to decrease with increasing age,
whereas PTH and calcium increases [49, 50]. Therefore,
we adjusted our analyses for age. We decided not to adjust
for menopause in our analysis, as menopause is heavily
dependent on age. In a sensitivity analysis, where we
stratified for menopause, the analysis showed similar
associations for postmenopausal women, but the analysis
was unstable regarding premenopausal women, due to
small numbers (n = 65) in this group.
Another factor that is known to affect serum levels of
25(OH)D is season [51], but as this factor was included in the
multivariate analysis, we consider that such variation ought to
have affected our results only to a minor extent.
Since all Swedish residents are given a unique civil
registration number, it is possible to link all women to
different registries. The Swedish Cause of Death Registry
that was used to retrieve information on cause of death, had
a coverage of 97.3 % in 2008 [52], and it has been shown
to be correct in 90 % of cases where malignant tumors is
the cause of death [53]. Therefore, it is expected that data
concerning cause of death is complete and correct to a
great extent.
As it has been previously shown that women within the
MDCS cohort have a higher incidence of breast cancer, but
lower breast cancer mortality, than non-participants, there
is a risk of a selection bias. The mortality risk between
participants in this study group and general population of
Malmo¨, hence, may differ. However, as there was a broad
distribution of 25OHD, and to some extent PTH in our
material, we consider that relative risks were less likely to
have been affected by a potential selection bias.
Primarily, we chose not to adjust for BMI in this study,
since previous studies have shown that a high BMI is asso-
ciated with low levels of vitamin D [54], and high BMI is also
associated with a poor prognosis [55]; hence, it may be part of
the casual pathway. A previous study has suggested the pos-
sibility of trapping vitamin D in subcutaneous fat [56].
Therefore, an adjustment for BMI could possibly have
masked an association between vitamin D levels and breast
cancer prognosis. When we stratified the analyses for normal
versus overweight, we noted that associations were stronger in
the overweight group compared to normal weight, which
could be explained by the above reasoning.
Since the analysis was adjusted for prognostic factors
that are used when deciding on adjuvant treatment, we
chose to present the analyses not adjusting for treatment as
this may have lead to an over-adjustment. Moreover, the
sensitivity analysis that included treatment showed similar
results as the main analysis.
Apart from the variables adjusted for in the present
analyses, there may have been other factors of interest,
such as information on human epidermal growth factor
receptor 2 (HER-2), which is a known prognostic factor
that influences both choice of treatment as well as prog-
nosis of a diagnosed breast cancer. Unfortunately many
tumors in our material were diagnosed before HER-2 was
recognized and used in clinical practice.
Fortunately, breast cancer-specific mortality is relatively
low, but this means few deaths from breast cancer in the
present study. Nonetheless, we were able to find statistically
significant data to support that pre-diagnostic 25OHD levels
influence mortality from breast cancer. In this analysis, we
could not find statistically significant associations between
pre-diagnostic levels of PTH and breast cancer survival and
also the association between levels of calcium and breast
cancer mortality was weak. Since outcome, i.e., deaths from
breast cancer are sparse, there is a possibility of type II error
and true associations could have been missed.
Conclusion
Women with pre-diagnostic 25OHD levels within the first
and third tertiles as compared to the second have a higher
breast cancer-specific mortality, i.e., a poor survival. There
Cancer Causes Control (2014) 25:1131–1140 1137
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was no association between pre-diagnostic levels of PTH
and breast cancer mortality. A weak association was seen
between high levels of pre-diagnostic calcium and low
breast cancer mortality. Our analysis suggests that vitamin
D levels may affect breast cancer survival, but that both
low and relatively high levels may have an adverse effect.
Acknowledgments This work was supported by The Swedish
Cancer Society, The Gunnar Nilsson Cancer Foundation, The Ernhold
Lundstro¨m Foundation, The Henning and Ida Persson Foundation,
The Einar and Inga Nilsson Foundation, The Malmo¨ University
Hospital Cancer Research Fund, The Ska˚ne University Hospital
Funds and Donations, The Breast Cancer network at Lund University
(BCLU), and The Region Ska˚ne (ALF). The authors want to thank Dr
Lola Anagnostaki, for pathologically examining all tumors diagnosed
between 1991–2004, and RN Anna Hwasser for data management.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
Appendix
See Table 4.
Table 4 Tertiles of vitamin D3
in relation to age and breast
cancer characteristics











Column percent (mean and SD in italics)
Age at diagnosis (years)
Mean 63.6 64.9 63.8 67.0 64.2
SD 7.8 7.8 8.0 8.8 7.9
Size
1–10 mm 24 29 28 18 27
11–20 mm 48 42 42 59 44
C21 mm 27 26 28 24 27
Unknown 2 3 2 0 2
Lymph node status
Positive 28 31 32 35 30
Negative 71 68 67 65 69
Unknown 1 1 1 0 1
Distant metastasis
Yes 1 1 2 0 1
No 99 99 98 100 98
Unknown 1 1 0 0 0
Nottingham grade
I 25 30 22 47 26
II 43 43 46 41 44
III 24 20 25 6 23
Unknown 8 7 7 6 7
Histological type
Ductal 68 67 63 71 66
Lobular 19 17 21 24 19
Other/mixed 6 12 9 0 9
Unknown 7 5 7 6 6
ER
0–10 % pos 12 8 12 6 11
[10 % pos 72 74 73 71 73
Unknown 16 18 16 24 17
PgR
0–10 % pos 43 33 40 35 39
[10 % pos 33 39 33 41 35
Unknown 24 28 27 24 26
1138 Cancer Causes Control (2014) 25:1131–1140
123
References
1. Colston KW (2008) Vitamin D and breast cancer risk. Best Pract
Res Clin Endocrinol Metab 22(4):587–599. doi:10.1016/j.beem.
2008.08.002
2. Rohan T (2007) Epidemiological studies of vitamin D and breast
cancer. Nutr Rev 65(Supplement 1):80. doi:10.1301/nr.2007.aug.
S80-S83
3. Grant WB (2010) An ecological study of cancer incidence and
mortality rates in France with respect to latitude, an index for
vitamin D production. Dermatoendocrinol 2(2):62–67. doi:10.
4161/derm.2.2.13624
4. Chen W, Armstrong BK, Rahman B, Zheng R, Zhang S, Cle-
ments M (2013) Relationship between cancer survival and
ambient ultraviolet B irradiance in China. Cancer Causes Control.
doi:10.1007/s10552-013-0210-4
5. Robsahm TE, Tretli S, Dahlback A, Moan J (2004) Vitamin D3
from sunlight may improve the prognosis of breast-, colon- and
prostate cancer (Norway). Cancer Causes Control 15(2):149–158.
doi:10.1023/B:CACO.0000019494.34403.09
6. Porojnicu A, Robsahm TE, Berg JP, Moan J (2007) Season of
diagnosis is a predictor of cancer survival. Sun-induced vitamin
D may be involved: a possible role of sun-induced Vitamin D.
J Steroid Biochem Mol Biol 103(3–5):675–678. doi:10.1016/j.
jsbmb.2006.12.031
7. Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J
(2010) Serum levels of vitamin D, PTH and calcium and breast
cancer risk-a prospective nested case–control study. Int J Cancer
127(9):2159–2168. doi:10.1002/ijc.25215
8. Gorham ED, Mohr SB, Garland FC, Garland CF (2009) Vitamin
D for cancer prevention and survival. Clin Rev Bone Miner
Metab 7(2):159–175. doi:10.1007/s12018-009-9028-8
9. Shao T, Klein P, Grossbard ML (2012) Vitamin D and breast cancer.
Oncologist 17(1):36–45. doi:10.1634/theoncologist.2011-0278
10. Rose AA, Elser C, Ennis M, Goodwin PJ (2013) Blood levels of
vitamin D and early stage breast cancer prognosis: a systematic
review and meta-analysis. Breast Cancer Res Treat
141(3):331–339. doi:10.1007/s10549-013-2713-9
11. Freedman DM, Looker AC, Chang SC, Graubard BI (2007)
Prospective study of serum vitamin D and cancer mortality in the
United States. J Natl Cancer Inst 99(21):1594–1602. doi:10.1093/
jnci/djm204
12. Steingrimsdottir L, Gunnarsson O, Indridason OS, Franzson L,
Sigurdsson G (2005) Relationship between serum parathyroid
hormone levels, vitamin D sufficiency, and calcium intake.
JAMA 294(18):2336–2341. doi:10.1001/jama.294.18.2336
13. Linforth R, Anderson N, Hoey R, Nolan T, Downey S, Brady G,
Ashcroft L, Bundred N (2002) Coexpression of parathyroid
hormone related protein and its receptor in early breast cancer
predicts poor patient survival. Clinical Cancer 8(10):3172–3177
14. Hoey RP, Sanderson C, Iddon J, Brady G, Bundred NJ, Anderson
NG (2003) The parathyroid hormone-related protein receptor is
expressed in breast cancer bone metastases and promotes auto-
crine proliferation in breast carcinoma cells. Br J Cancer
88(4):567–573. doi:10.1038/sj.bjc.6600757
15. Birch MA, Carron JA, Scott M, Fraser WD, Gallagher JA (1995)
Parathyroid hormone (PTH)/PTH-related protein (PTHrP)
receptor expression and mitogenic responses in human breast
cancer cell lines. Br J Cancer 72(1):90–95
16. Cataisson C, Lieberherr M, Cros M, Gauville C, Graulet AM,
Cotton J, Calvo F, de Vernejoul MC, Foley J, Bouizar Z (2000)
Parathyroid hormone-related peptide stimulates proliferation of
highly tumorigenic human SV40-immortalized breast epithelial
cells. J Bone Miner 15(11):2129–2139. doi:10.1359/jbmr.2000.
15.11.2129
17. Palmer M, Adami HO, Krusemo UB, Ljunghall S (1988)
Increased risk of malignant diseases after surgery for primary
hyperparathyroidism. A nationwide cohort study. Am J Epi-
demiol 127(5):1031–1040
18. Michels KB, Xue F, Brandt L, Ekbom A (2004) Hyperparathy-
roidism and subsequent incidence of breast cancer. Int J Cancer
110(3):449–451. doi:10.1002/ijc.20155
19. Nilsson IL, Zedenius J, Yin L, Ekbom A (2007) The association
between primary hyperparathyroidism and malignancy: nation-
wide cohort analysis on cancer incidence after parathyroidec-
tomy. Endocr Relat Cancer 14(1):135–140. doi:10.1677/erc.1.
01261
20. Pickard AL, Gridley G, Mellemkjae L, Johansen C, Kofoed-
Enevoldsen A, Cantor KP, Brinton LA (2002) Hyperparathy-
roidism and subsequent cancer risk in Denmark. Cancer
95(8):1611–1617. doi:10.1002/cncr.10846
21. Almquist M, Manjer J, Bondeson L, Bondeson A-G (2007)
Serum calcium and breast cancer risk: results from a prospective
cohort study of 7,847 women. Cancer Causes Control
18(6):595–602. doi:10.1007/s10552-007-9001-0
22. Ramasamy I (2006) Recent advances in physiological calcium
homeostasis. Clin Chem Lab Med 44(3):237–273. doi:10.1515/
CCLM.2006.046
23. Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, Lind-
strom M, Mattisson I, Berglund G (2001) The Malmo Diet and
Cancer Study: representativity, cancer incidence and mortality in
participants and non-participants. Eur J Cancer Prev
10(6):489–499
24. Butt S (2011) Reproductive factors and breast cancer—parity,
breastfeeding and genetic predisposition in relation to risk and
prognosis. Lund University, Faculty of Medicine Doctoral Dis-
sertation Series, 10
25. Borgquist S, Anagnostaki L, Jirstrom K, Landberg G, Manjer J
(2007) Breast tumours following combined hormone replacement
therapy express favourable prognostic factors. Int J Cancer
120(10):2202–2207. doi:10.1002/ijc.22542
26. Wallstro¨m P, Department of Clinical Sciences M, Lund U,
Emergency mMS, Internal M, Lunds u, Institutionen fo¨r kliniska
vetenskaper M, Faculty of M, Medicin, Sektionen fo¨r AMK
(2002) Diet, lifestyle, antioxidants, and biomarkers of cancer risk:
an epidemiological report from the Malmo¨ Diet and Cancer
cohort. Dissertation/Thesis, Univ.-sjukhuset MAS, Malmo¨
27. Anker P, Wieland E, Ammann D, Dohner RE, Asper R, Simon W
(1981) Neutral carrier based ion-selective electrode for the
determination of total calcium in blood serum. Anal Chem
53(13):1970–1974
28. Gross M, Kost SB, Ennis B, Stumpf W, Kumar R (1986) Effect of
1,25-dihydroxyvitamin D3 on mouse mammary tumor (GR) cells:
evidence for receptors, cellular uptake, inhibition of growth and
alteration in morphology at physiologic concentrations of hormone.
J Bone Miner Res 1(5):457–467. doi:10.1002/jbmr.5650010510
29. Simboli-Campbell M, Gagnon A, Franks DJ, Welsh J (1994)
1,25-Dihydroxyvitamin D3 translocates protein kinase C beta to
nucleus and enhances plasma membrane association of protein
kinase C alpha in renal epithelial cells. J Biol Chem
269(5):3257–3264
30. Fleet JC, DeSmet M, Johnson R, Li Y (2012) Vitamin D and
cancer: a review of molecular mechanisms. Biochem J
441(1):61–76. doi:10.1042/BJ20110744
31. Leyssens C, Verlinden L, Verstuyf A (2013) Antineoplastic
effects of 1,25(OH)2D3 and its analogs in breast, prostate and
colorectal cancer. Endocr Relat Cancer 20(2):R31–R47. doi:10.
1530/erc-12-0381
32. Grant WB, Peiris AN (2012) Differences in vitamin D status may
account for unexplained disparities in cancer survival rates
Cancer Causes Control (2014) 25:1131–1140 1139
123
between African and white Americans. Dermatoendocrinol
4(2):85–94. doi:10.4161/derm.19667
33. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N (2009)
Prognostic effects of 25-hydroxyvitamin D levels in early breast
cancer. J Clin Oncol 27(23):3757–3763. doi:10.1200/JCO.2008.
20.0725
34. Tretli S, Schwartz GG, Torjesen PA, Robsahm TE (2012) Serum
levels of 25-hydroxyvitamin D and survival in Norwegian
patients with cancer of breast, colon, lung, and lymphoma: a
population-based study. Cancer Causes Control 23(2):363–370.
doi:10.1007/s10552-011-9885-6
35. Hatse S, Lambrechts D, Verstuyf A, Smeets A, Brouwers B,
Vandorpe T, Brouckaert O, Peuteman G, Laenen A, Verlinden L,
Kriebitzsch C, Dieudonne AS, Paridaens R, Neven P, Christiaens
MR, Bouillon R, Wildiers H (2012) Vitamin D status at breast
cancer diagnosis: correlation with tumor characteristics, disease
outcome, and genetic determinants of vitamin D insufficiency.
Carcinogenesis 33(7):1319–1326. doi:10.1093/carcin/bgs187
36. Villasenor A, Ballard-Barbash R, Ambs A, Bernstein L, Baum-
gartner K, Baumgartner R, Ulrich CM, Hollis BW, McTiernan A,
Neuhouser ML (2013) Associations of serum 25-hydroxyvitamin
D with overall and breast cancer-specific mortality in a multi-
ethnic cohort of breast cancer survivors. Cancer Causes Control
24(4):759–767. doi:10.1007/s10552-013-0158-4
37. Vrieling A, Hein R, Abbas S, Schneeweiss A, Flesch-Janys D,
Chang-Claude J (2011) Serum 25-hydroxyvitamin D and post-
menopausal breast cancer survival: a prospective patient cohort
study. Breast Cancer Res 13(4):R74. doi:10.1186/bcr2920
38. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM,
Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones
G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA (2011) The
2011 report on dietary reference intakes for calcium and vitamin
D from the Institute of Medicine: what clinicians need to know.
J Clin Endocrinol Metab 96(1):53–58. doi:10.1210/jc.2010-2704
39. Brandstedt J, Almquist M, Manjer J, Malm J (2012) Vitamin D,
PTH, and calcium and the risk of prostate cancer: a prospective
nested case–control study. Cancer Causes Control
23(8):1377–1385. doi:10.1007/s10552-012-9948-3
40. Isowa S, Shimo T, Ibaragi S, Kurio N, Okui T, Matsubara K,
Hassan NM, Kishimoto K, Sasaki A (2010) PTHrP regulates
angiogenesis and bone resorption via VEGF expression. Anti-
cancer Res 30(7):2755–2767
41. Ankrah-Tetteh T, Wijeratne S, Swaminathan R (2008) Intrain-
dividual variation in serum thyroid hormones, parathyroid hor-
mone and insulin-like growth factor-1. Ann Clin Biochem 45(Pt
2):167–169. doi:10.1258/acb.2007.007103
42. Viljoen A, Singh DK, Twomey PJ, Farrington K (2008) Ana-
lytical quality goals for parathyroid hormone based on biological
variation. Clin Chem Lab Med 46(10):1438–1442. doi:10.1515/
CCLM.2008.275
43. Thaw SS, Sahmoun A, Schwartz GG (2012) Serum calcium,
tumor size, and hormone receptor status in women with untreated
breast cancer. Cancer Biol Ther 13(7):467–471. doi:10.4161/cbt.
19606
44. Almquist M, Anagnostaki L, Bondeson L, Bondeson AG, Borg-
quist S, Landberg G, Malina J, Malm J, Manjer J (2009) Serum
calcium and tumour aggressiveness in breast cancer: a prospec-
tive study of 7847 women. Eur J Cancer Prev 18(5):354–360.
doi:10.1097/CEJ.0b013e32832c386f
45. Meng JE, Hovey KM, Wactawski-Wende J, Andrews CA, La-
monte MJ, Horst RL, Genco RJ, Millen AE (2012) Intraindi-
vidual variation in plasma 25-hydroxyvitamin D measures
5 years apart among postmenopausal women. Cancer Epidemiol
Biomarkers Prev 21(6):916–924. doi:10.1158/1055-9965.EPI-12-
0026
46. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci
E (2004) Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and
subsequent risk of prostate cancer. Cancer Causes Control
15(3):255–265. doi:10.1023/B:CACO.0000024245.24880.8a
47. Gallagher SK, Johnson LK, Milne DB (1989) Short-term and
long-term variability of indices related to nutritional status. I: Ca,
Cu, Fe, Mg, and Zn. Clin Chem 35(3):369–373
48. Ricos C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A,
Jimenez CV, Minchinela J, Perich C, Simon M (1999) Current
databases on biological variation: pros, cons and progress. Scand
J Clin Lab Invest 59(7):491–500
49. Lips P (2006) Vitamin D physiology. Prog Biophys Mol Biol
92(1):4–8. doi:10.1016/j.pbiomolbio.2006.02.016
50. Need AG, O’Loughlin PD, Morris HA, Horowitz M, Nordin BE
(2004) The effects of age and other variables on serum para-
thyroid hormone in postmenopausal women attending an osteo-
porosis center. J Clin Endocrinol Metab 89(4):1646–1649
51. Lips P, van Schoor NM, de Jongh RT (2014) Diet, sun, and
lifestyle as determinants of vitamin D status. Ann N Y Acad Sci.
doi:10.1111/nyas.12443
52. Welfare NBoHa (2010) Cause of death statistics; history, pro-
duction and reliability (in Swedish). http://www.socialstyrelsen.
se/publikationer2010/2010-4-33. Accessed 21 Dec 2013
53. Johansson LA, Bjorkenstam C, Westerling R (2009) Unexplained
differences between hospital and mortality data indicated mis-
takes in death certification: an investigation of 1,094 deaths in
Sweden during 1995. J Clin Epidemiol 62(11):1202–1209.
doi:10.1016/j.jclinepi.2009.01.010
54. Brock K, Huang WY, Fraser DR, Ke L, Tseng M, Stolzenberg-
Solomon R, Peters U, Ahn J, Purdue M, Mason RS, McCarty C,
Ziegler RG, Graubard B (2010) Low vitamin D status is associ-
ated with physical inactivity, obesity and low vitamin D intake in
a large US sample of healthy middle-aged men and women.
J Steroid Biochem Mol Biol 121(1–2):462–466. doi:10.1016/j.
jsbmb.2010.03.091
55. Pajares B, Pollan M, Martin M, Mackey JR, Lluch A, Gavila J,
Vogel C, Ruiz-Borrego M, Calvo L, Pienkowski T, Rodriguez-
Lescure A, Segui MA, Tredan O, Anton A, Ramos M, Del Car-
men M, Rodriguez-Martin C, Carrasco E, Alba E (2013) Obesity
and survival in operable breast cancer patients treated with
adjuvant anthracyclines and taxanes according to pathological
subtypes: a pooled analysis. Breast Cancer Res 15(6):R105.
doi:10.1186/bcr3572
56. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF (2000)
Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr
72(3):690–693
1140 Cancer Causes Control (2014) 25:1131–1140
123
